How effective is tirzepatide-supported digital weight-loss care in the real world?
A new study published in Diabetes, Obesity and Metabolism has evaluated 6- and 12-month weight-loss outcomes, adherence rates and predictors of success in Australian patients using the Juniper digital weight-loss service (DWLS) with tirzepatide support.
While clinical trial evidence for tirzepatide is strong, real-world data from digital obesity services, particularly those that combine pharmacotherapy with multidisciplinary lifestyle coaching, have remained limited. This study aimed to fill that gap for the Australian context, examining both the outcomes achievable under sustained adherence and those seen across the full, unfiltered patient cohort.
At 12 months, adherent Juniper AU patients achieved a mean weight loss of 22.7%, and every single one of them reached the clinically meaningful milestone of ≥5% weight reduction.
Understanding the results
What did the study find?
All 4,309 patients who initiated tirzepatide through the Juniper AU DWLS between September 2024 and April 2025 were included in the analysis. The study population was predominantly female (92.9%) with a mean age of 41.46 years and a mean baseline BMI of 32.9 kg/m². Two cohorts were assessed: an adherent cohort (patients who met minimum medication order and weight data submission criteria) and a full cohort (all patients, analysed using last observation carried forward imputation).
The study revealed that:
- 34.8% of patients adhered to their 12-month medication schedule; 59.4% adhered to their 6-month schedule
- At 6 months, 31.7% of patients met study inclusion criteria. Among this group, mean weight loss was 16.9%, with 98.0% achieving a clinically meaningful reduction of ≥5% body weight.
- At 12 months, 16.1% of patients satisfied study inclusion criteria. This group achieved a mean weight loss of 22.7%, and 100% reached the ≥5% milestone — a result that compares favourably with tirzepatide clinical trial benchmarks.
- Early clinical response and sustained engagement were identified as key drivers of adherence, suggesting that patients who see results early and remain active in the program are significantly more likely to persist with treatment over the longer term.
- Adherence remains the central challenge. The gap between adherent and full-cohort outcomes underscores that while tirzepatide, paired with multidisciplinary digital care, delivers substantial weight loss for engaged users, low program retention limits its population-level impact.
- Side effect rates were common but predominantly mild or moderate, consistent with findings from previous studies of semaglutide-supported digital weight-loss services.
What the adherence gap means for digital obesity care
This study adds important real-world evidence to the growing literature on medicated digital weight-loss services, and its conclusions point in two clear directions.
For patients who engage consistently with the Juniper program, tirzepatide-supported digital care delivers clinically meaningful and in some cases exceptional weight-loss outcomes. A 22.7% mean weight loss at 12 months among adherent patients places the program's results in the same range as those observed in controlled clinical trials.
But the study's findings also make clear that maximising the public health potential of these services will require more than effective pharmacotherapy. Strategies to improve long-term adherence, manage patient expectations in the early stages of treatment, and address the cost barriers that drive discontinuation will be essential, particularly in an unsubsidised setting where program fees represent a significant ongoing commitment for patients.
